Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M288Revenue $M4.4Net Margin (%)-865.5Z-Score-4.3
Enterprise Value $M312EPS $-0.8Operating Margin %-1,248.5F-Score3
P/E(ttm))0Cash Flow Per Share $-0.3Pre-tax Margin (%)-1,247.6Higher ROA y-yN
Price/Book34.610-y EBITDA Growth Rate %34.0Quick Ratio1.7Cash flow > EarningsY
Price/Sales38.45-y EBITDA Growth Rate %62.8Current Ratio1.7Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-84.8Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)3ROE % (ttm)-299.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M83.1ROI % (ttm)-119.2Gross Margin Increase y-yY

Gurus Latest Trades with BTX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

BTX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


BTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Russell Angus C.Director 2014-12-12Sell0$0view
Cartt Stephen LaHueDirector 2014-11-04Sell0$0view
SCHLACHET DAVIDDirector 2014-10-08Buy32,050$3.1211.86view
FARRELL STEPHEN CDirector 2014-10-08Buy32,050$3.1211.86view
Peabody RobertSr. VP, COO, and CFO 2014-07-22Sell100,000$2.6531.7view
WEST MICHAEL DCEO 2014-07-22Sell270,000$2.6531.7view
BROADWOOD PARTNERS LPDirector, 10% Owner 2014-07-22Buy370,000$2.6531.7view
TEW WILLIAM P PHDChief Commercial Officer 2014-06-17Sell30,000$3.0713.68view
BROADWOOD PARTNERS LPDirector, 10% Owner 2014-06-16Buy1,000,000$2.539.6view
BROADWOOD PARTNERS LPDirector, 10% Owner 2014-05-16Buy300,000$2.4542.45view

Press Releases about BTX :

    Quarterly/Annual Reports about BTX:

    News about BTX:

    Articles On GuruFocus.com
    Weekly CFO Buys Highlight: BTX, CWST, BKSC, STAG Jun 27 2011 
    Weekly CEO Buys Highlight: PCYC, HLX, FSC, CREG, BTX Jun 25 2011 

    More From Other Websites
    BioTime Subsidiary ES Cell International and GE Healthcare Cross-License patents in the Field of... Dec 15 2014
    12:02 pm BioTime announced that its subsidiary ES Cell International and GE Healthcare have signed a... Dec 15 2014
    BioTime Subsidiary ES Cell International and GE Healthcare Cross-License patents in the Field of... Dec 15 2014
    BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment of Clinical Study of... Dec 15 2014
    BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment of Clinical Study of... Dec 15 2014
    BioTime Appoints Angus C. Russell to Board of Directors Dec 15 2014
    BioTime Appoints Angus C. Russell to Board of Directors Dec 15 2014
    BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Dec 15 2014
    BioTime to Host Investor and Analyst Day on December 15, 2014 Dec 12 2014
    BioTime to Host Investor and Analyst Day on December 15, 2014 Dec 12 2014
    BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Dec 04 2014
    BioTime to Present at the LD Micro VII Conference Dec 03 2014
    BIOTIME INC Financials Nov 15 2014
    BIOTIME INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Nov 10 2014
    Asterias Biotherapeutics Reports Third Quarter Financial and Operating Results Nov 10 2014
    Asterias Biotherapeutics Reports Third Quarter Financial and Operating Results Nov 10 2014
    BioTime Reports Third Quarter Results and Recent Progress Nov 10 2014
    BIOTIME INC Files SEC form 10-Q, Quarterly Report Nov 07 2014
    BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Nov 04 2014
    BioTime Receives Authorization to Begin Pivotal Human Clinical Trial of Renevia™ in Europe Nov 04 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK